➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
AstraZeneca
Express Scripts
McKesson

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Patent: 9,358,307

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,358,307
Title:Targeting of innate immune response to tumor site
Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
Inventor(s): Pitcovski; Jacob (Korazim, IL), Shahar; Ehud (Kiryat Shmona, IL), Gorodetsky; Raphael (Jerusalem, IL)
Assignee: GAVISH-GALILEE BIO APPLICATIONS LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL)
Application Number:12/864,550
Patent Claims:see list of patent claims

Details for Patent 9,358,307

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial GAVISH-GALILEE BIO APPLICATIONS LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL) 2039-02-26 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial GAVISH-GALILEE BIO APPLICATIONS LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL) 2039-02-26 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial GAVISH-GALILEE BIO APPLICATIONS LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL) 2039-02-26 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial GAVISH-GALILEE BIO APPLICATIONS LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKinsey
Mallinckrodt
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.